Bristol-Myers Squibb Company

NYSE: BMY
$49.41
+$0.39 (+0.8%)
Closing Price on September 20, 2024

BMY Articles

Ardea Biosciences, Inc. (NASDAQ: RDEA) is soaring today on news that AstraZeneca PLC (NYSE: AZN) is paying about $1.26 billion to acquire the company.  With another small-cap to mid-cap biotech and...
Diabetes drug maker Amylin Pharmaceuticals Inc. (NASDAQ: AMLN) has hired bankers and lawyers to help the company find a buyer. In February Amylin turned down a $3.5 billion ($22/share) offer from...
The data is from a major union, and, therefore, may have a bias against chief executives. Numbers can be bent. The AFL-CIO reports that CEO pay rose 14% last year: According to data released by the...
After legal issues slowed their progress last year, foreclosures are about to increase. (Reuters) Time Warner Cable (NYSE: TWC) may end its deal with Current TV because of low ratings. (Reuters) The...
If there was a merger candidate which ever made sense in biotech and pharma it is Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN).  News from Bloomberg is out that the company has rejected an offer to...
Anheuser-Busch InBev NV may buy China’s Kingway Brewery Holdings’ assets. (Reuters) The Department of Justice is expected to widen its probe of mortgage-backed securities. (Reuters) AT&T...
All three major US indexes opened higher this morning, but enthusiasm tapered off quickly and steadily, if not sharply. A drop in the number of new home sales and a smaller-than-expected rise in the...
The tide of patent expirations that is washing over big pharmaceutical houses is cresting now and investors have begun looking forward to how these companies will deal with some sharp blows to their...
Deal makers were busy over the weekend. Strategic considerations were more the driver of activity than an improved economy, however. Lions Gate Entertainment (NYSE: LGF) will buy Summit Entertainment...